Hoth Therapeutics Files 2024 Annual Report

TL;DR

HOTH filed its 2024 10-K. All systems go for pharma prep.

AI Summary

Hoth Therapeutics, Inc. filed its 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Nevada with its principal executive offices in New York, operates in the Pharmaceutical Preparations sector. The filing covers its annual report and includes details about its business, financial condition, and operations.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Hoth Therapeutics' performance and strategic direction for the fiscal year 2024, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Hoth Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the reporting period for financial statements.)
• 2024 — Fiscal Year (The period covered by the annual report.)

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• 2024 (date) — Fiscal year end
• Nevada (jurisdiction) — State of incorporation
• New York (location) — Principal executive offices
• 001-38803 (identifier) — Commission file number

FAQ

From the Filing

0001013762-25-004108.txt : 20250328 0001013762-25-004108.hdr.sgml : 20250328 20250328161547 ACCESSION NUMBER: 0001013762-25-004108 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250328 DATE AS OF CHANGE: 20250328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 25786481 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 10-K 1 ea0233805-10k_hoth.htm ANNUAL REPORT     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the fiscal year ended December 31 , 2024   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from ______ to ______   Commission file number 001-38803   HOTH THERAPEUTICS, INC. (Exact name of registrant as specified in charter)   Nevada   82-1553794 (State or other jurisdiction of incorporation or organization)   I.R.S. Employer Identification No.   1177 Avenue of the Americas , 5 th Floor , Suite 5066 , New York, New York   10036 (Address of principal executive offices)   (Zip code)   (646) 756-2997 (Registrant’s telephone number, including area code)   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered Common Stock, par value $0.0001 per share   HOTH   The Nasdaq Stock Market LLC   Securities registered pursuant to Section 12(g) of the Act: None.   Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒   Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company   ☒     Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accoun